A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
Identifieur interne : 000116 ( Ncbi/Merge ); précédent : 000115; suivant : 000117A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
Auteurs : O. Rascol [France] ; D J Brooks ; A D Korczyn ; P P De Deyn ; C E Clarke ; A E LangSource :
- The New England journal of medicine [ 0028-4793 ] ; 2000.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Disease-Free Survival, Double-Blind Method, Drug Therapy, Combination, Dyskinesia, Drug-Induced (epidemiology), Dyskinesia, Drug-Induced (etiology), Dyskinesia, Drug-Induced (prevention & control), Female, Humans, Incidence, Indoles (adverse effects), Indoles (therapeutic use), Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Prospective Studies, Risk Factors.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Indoles, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Indoles, Levodopa.
- drug therapy : Parkinson Disease.
- epidemiology : Dyskinesia, Drug-Induced.
- etiology : Dyskinesia, Drug-Induced.
- prevention & control : Dyskinesia, Drug-Induced.
- Aged, Disease-Free Survival, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Incidence, Male, Middle Aged, Prospective Studies, Risk Factors.
Abstract
There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist.
DOI: 10.1056/NEJM200005183422004
PubMed: 10816186
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001313
- to stream PubMed, to step Curation: 001272
- to stream PubMed, to step Checkpoint: 001272
Links to Exploration step
pubmed:10816186Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Investigation Center, Neuropharmacology Unit, INSERM Unité 455, University Hospital, Toulouse, France. rascol@cict.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Center, Neuropharmacology Unit, INSERM Unité 455, University Hospital, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D J" last="Brooks">D J Brooks</name>
</author>
<author><name sortKey="Korczyn, A D" sort="Korczyn, A D" uniqKey="Korczyn A" first="A D" last="Korczyn">A D Korczyn</name>
</author>
<author><name sortKey="De Deyn, P P" sort="De Deyn, P P" uniqKey="De Deyn P" first="P P" last="De Deyn">P P De Deyn</name>
</author>
<author><name sortKey="Clarke, C E" sort="Clarke, C E" uniqKey="Clarke C" first="C E" last="Clarke">C E Clarke</name>
</author>
<author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A E" last="Lang">A E Lang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:10816186</idno>
<idno type="pmid">10816186</idno>
<idno type="doi">10.1056/NEJM200005183422004</idno>
<idno type="wicri:Area/PubMed/Corpus">001313</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001313</idno>
<idno type="wicri:Area/PubMed/Curation">001272</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001272</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001272</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001272</idno>
<idno type="wicri:Area/Ncbi/Merge">000116</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Investigation Center, Neuropharmacology Unit, INSERM Unité 455, University Hospital, Toulouse, France. rascol@cict.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Center, Neuropharmacology Unit, INSERM Unité 455, University Hospital, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D J" last="Brooks">D J Brooks</name>
</author>
<author><name sortKey="Korczyn, A D" sort="Korczyn, A D" uniqKey="Korczyn A" first="A D" last="Korczyn">A D Korczyn</name>
</author>
<author><name sortKey="De Deyn, P P" sort="De Deyn, P P" uniqKey="De Deyn P" first="P P" last="De Deyn">P P De Deyn</name>
</author>
<author><name sortKey="Clarke, C E" sort="Clarke, C E" uniqKey="Clarke C" first="C E" last="Clarke">C E Clarke</name>
</author>
<author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A E" last="Lang">A E Lang</name>
</author>
</analytic>
<series><title level="j">The New England journal of medicine</title>
<idno type="ISSN">0028-4793</idno>
<imprint><date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Disease-Free Survival</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia, Drug-Induced (epidemiology)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Dyskinesia, Drug-Induced (prevention & control)</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Indoles (adverse effects)</term>
<term>Indoles (therapeutic use)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Prospective Studies</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Indoles</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Indoles</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Disease-Free Survival</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
<term>Risk Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10816186</PMID>
<DateCreated><Year>2000</Year>
<Month>05</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>2000</Year>
<Month>05</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>11</Month>
<Day>26</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-4793</ISSN>
<JournalIssue CitedMedium="Print"><Volume>342</Volume>
<Issue>20</Issue>
<PubDate><Year>2000</Year>
<Month>May</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>The New England journal of medicine</Title>
<ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.</ArticleTitle>
<Pagination><MedlinePgn>1484-91</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">In this prospective, randomized, double-blind study, we compared the safety and efficacy of the dopamine D2-receptor agonist ropinirole with that of levodopa over a period of five years in 268 patients with early Parkinson's disease. If symptoms were not adequately controlled by the assigned study medication, patients could receive supplementary levodopa, administered in an open-label fashion. The primary outcome measure was the occurrence of dyskinesia.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty-five of the 179 patients in the ropinirole group (47 percent) and 45 of the 89 patients in the levodopa group (51 percent) completed all five years of the study. In the ropinirole group 29 of the 85 patients (34 percent) received no levodopa supplementation. The analysis of the time to dyskinesia showed a significant difference in favor of ropinirole (hazard ratio for remaining free of dyskinesia, 2.82; 95 percent confidence interval, 1.78 to 4.44; P<0.001). At five years, the cumulative incidence of dyskinesia (excluding the three patients who had dyskinesia at base line), regardless of levodopa supplementation, was 20 percent (36 of 177 patients) in the ropinirole group and 45 percent (40 of 88 patients) in the levodopa group. There was no significant difference between the two groups in the mean change in scores for activities of daily living among those who completed the study. Adverse events led to the early withdrawal from the study of 48 of 179 patients in the ropinirole group (27 percent) and 29 of 89 patients in the levodopa group (33 percent). The mean (+/-SD) daily doses given by the end of the study were 16.5+/-6.6 mg of ropinirole (plus 427+/-221 mg of levodopa in patients who received supplementation) and 753+/-398 mg of levodopa (including supplements).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early Parkinson's disease can be managed successfully for up to five years with a reduced risk of dyskinesia by initiating treatment with ropinirole alone and supplementing it with levodopa if necessary.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rascol</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Clinical Investigation Center, Neuropharmacology Unit, INSERM Unité 455, University Hospital, Toulouse, France. rascol@cict.fr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brooks</LastName>
<ForeName>D J</ForeName>
<Initials>DJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Korczyn</LastName>
<ForeName>A D</ForeName>
<Initials>AD</Initials>
</Author>
<Author ValidYN="Y"><LastName>De Deyn</LastName>
<ForeName>P P</ForeName>
<Initials>PP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Clarke</LastName>
<ForeName>C E</ForeName>
<Initials>CE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lang</LastName>
<ForeName>A E</ForeName>
<Initials>AE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>N Engl J Med</MedlineTA>
<NlmUniqueID>0255562</NlmUniqueID>
<ISSNLinking>0028-4793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>030PYR8953</RegistryNumber>
<NameOfSubstance UI="C046649">ropinirole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2000 Sep 21;343(12):884; author reply 885</RefSource>
<PMID Version="1">11001684</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2000 Sep 21;343(12):885</RefSource>
<PMID Version="1">11001687</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2000 Sep 21;343(12):885</RefSource>
<PMID Version="1">11001686</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2000 Sep 21;343(12):884; author reply 885</RefSource>
<PMID Version="1">11001685</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year>
<Month>5</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2000</Year>
<Month>5</Month>
<Day>29</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2000</Year>
<Month>5</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10816186</ArticleId>
<ArticleId IdType="doi">10.1056/NEJM200005183422004</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
</region>
<settlement><li>Toulouse</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D J" last="Brooks">D J Brooks</name>
<name sortKey="Clarke, C E" sort="Clarke, C E" uniqKey="Clarke C" first="C E" last="Clarke">C E Clarke</name>
<name sortKey="De Deyn, P P" sort="De Deyn, P P" uniqKey="De Deyn P" first="P P" last="De Deyn">P P De Deyn</name>
<name sortKey="Korczyn, A D" sort="Korczyn, A D" uniqKey="Korczyn A" first="A D" last="Korczyn">A D Korczyn</name>
<name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A E" last="Lang">A E Lang</name>
</noCountry>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000116 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000116 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:10816186 |texte= A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:10816186" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |